These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 25639024)
1. [Management of cutaneous adverse events induced by molecularly-targeted drugs]. Nakahara T Fukuoka Igaku Zasshi; 2014 Sep; 105(9):175-81. PubMed ID: 25639024 [No Abstract] [Full Text] [Related]
2. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Hammond-Thelin LA Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775 [TBL] [Abstract][Full Text] [Related]
3. [Management of adverse effects of targeted therapy toxicities in oncology]. Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060 [TBL] [Abstract][Full Text] [Related]
4. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors. Lisi P; Bellini V; Bianchi L Oncology; 2014; 87(5):311-9. PubMed ID: 25196815 [TBL] [Abstract][Full Text] [Related]
7. Skin care for cancer patients. Lacouture ME Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263 [No Abstract] [Full Text] [Related]
8. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698 [TBL] [Abstract][Full Text] [Related]
9. Skin toxicity of targeted cancer agents: mechanisms and intervention. Belum VR; Fontanilla Patel H; Lacouture ME; Rodeck U Future Oncol; 2013 Aug; 9(8):1161-70. PubMed ID: 23902247 [TBL] [Abstract][Full Text] [Related]
10. Zinc supplements may prevent and treat cutaneous toxicities induced by epidermal growth factor receptor inhibitors. Gonçalo M J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):220-221. PubMed ID: 36640375 [No Abstract] [Full Text] [Related]
11. [Managing cutaneous toxicities of targeted therapies]. Kiyohara Y Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009 [TBL] [Abstract][Full Text] [Related]
12. Erlotinib-associated skin reactions - case report and proposal for classification. Zoller A; Schäd SG; Gross GE Br J Dermatol; 2006 Dec; 155(6):1293-5. PubMed ID: 17107405 [No Abstract] [Full Text] [Related]
13. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. Ransohoff JD; Kwong BY Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Bianchini D; Jayanth A; Chua YJ; Cunningham D Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575 [TBL] [Abstract][Full Text] [Related]
15. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Lacouture ME Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987 [TBL] [Abstract][Full Text] [Related]
16. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072 [TBL] [Abstract][Full Text] [Related]
17. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Fox LP Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980 [TBL] [Abstract][Full Text] [Related]
18. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors. Sinclair R Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509 [TBL] [Abstract][Full Text] [Related]